GEN1286 / Genmab - LARVOL DELTA

A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=23 | Terminated | Sponsor: Genmab | Not yet recruiting ➔ Terminated; Genmab has decided to terminate the GEN1286 program due to an unfavorable benefit-risk profile not supporting further development.

Trial termination • Oncology • Solid Tumor

A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=23 | Terminated | Sponsor: Genmab | Trial completion date: Jun 2028 ➔ Mar 2026 | Active, not recruiting ➔ Terminated | Trial primary completion date: May 2028 ➔ Mar 2026; Genmab has decided to terminate the GEN1286 program due to an unfavorable benefit-risk profile not supporting further development.

Trial completion date • Trial primary completion date • Trial termination • Oncology • Solid Tumor

A Novel EGFR x cMET bispecific ADC PRO1286 demonstrated broad antitumor activity and promising tolerability in preclinical models (AACR 2024) - "Sesutecan previously demonstrated promising characteristics in preclinical studies with multiple targets and conferred an encouraging benefit:risk profile in the clinic with a FRα-directed ADC (rinatabart sesutecan). It may also differentiate from existing EGFR- and/or cMET-targeting agents on broad coverage of EGFR and cMET-expressing tumors with or without the respective AGAs. Effort is under way to advance a DAR optimized molecule to the clinic for the treatment of many EGFR- or cMET-expressing solid tumors."

ADC • Bispecific • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • FOLR1

A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=23 | Active, not recruiting | Sponsor: Genmab | Recruiting ➔ Active, not recruiting | N=260 ➔ 23

Enrollment change • Enrollment closed • Solid Tumor

Trial to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activity of GEN1286 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=214 | Recruiting | Sponsor: Genmab | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

Genmab/Pufang Bio: EGFR/cMET dual-antibody ADC starts phase 1/2 clinical trial [Google translation] (vbdata.cn) - "Genmab has launched a Phase 1/2 clinical trial of EGFR/cMET dual-antibody ADC, with plans to enroll 214 patients, which is expected to be completed in 2028."

New P1/2 trial • Oncology

ProfoundBio to Present Data on Multiple Preclinical Programs From Its Antibody-Drug Conjugate Pipeline at the American Association for Cancer Research Annual Meeting 2024 (PRNewswire) - "ProfoundBio...announced its participation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024....ProfoundBio will showcase its innovative ADC programs through an oral presentation on its EGFR- and cMET-dual targeting ADC PRO1286, a poster presentation detailing preclinical data of a SLITRK6-directed ADC PRO1106, and a late-breaking poster presentation on a CD98-directed ADC developed in partnership with Huahui Health, a clinical-stage biotechnology company."

Late-breaking abstract • Preclinical • Oncology